(+/-)-2,4-dimethyl-1,2,3,4-tetrahydroisoquinoline | 20666-00-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 四氢异喹啉
• 英文名称: (+/-)-2,4-dimethyl-1,2,3,4-tetrahydroisoquinoline
• 英文别名: 2,4-dimethyl-1,2,3,4-tetrahydroisoquinoline；N,4-dimethyl-1,2,3,4-tetrahydroisoquinoline；2,4-dimethyl-1,2,3,4-tetrahydro-isoquinoline；2,4-Dimethyl-1,2,3,4-tetrahydroisochinolin；2,4-dimethyl-3,4-dihydro-1H-isoquinoline
• CAS: 20666-00-6
• 化学式: C₁₁H₁₅N
• 分子量: 161.247
• InChiKey: XGXBWNUSKRIFMX-UHFFFAOYSA-N

物化性质

• 沸点：
  120 °C(Press: 15 Torr)
• 密度：
  0.963±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  3.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  (+/-)-2,4-dimethyl-1,2,3,4-tetrahydroisoquinoline 、 六羰基铬 以 四氢呋喃 、 二丁醚 为溶剂， 以10%的产率得到(+/-)-tricarbonyl(η6-endo-2,4-dimethyl-1,2,3,4-tetrahydroisoquinoline)chromium(0)
  参考文献：
  名称：

  Coote, Steven J.; Davies, Stephen G.; Sutton, Kevin H., Journal of the Chemical Society. Perkin transactions I, 1988, p. 1481 - 1488

  摘要：

  DOI：
• 作为产物：
  描述：

  N-allyl-N-α-methylbenzylamine 在 PPA 作用下， 以 氯仿 为溶剂， 反应 2.0h， 以50%的产率得到(+/-)-2,4-dimethyl-1,2,3,4-tetrahydroisoquinoline
  参考文献：
  名称：

  Euerby, Melvin R.; Waigh, Roger D., Journal of Chemical Research, Miniprint, 1987, # 2, p. 554 - 575

  摘要：

  DOI：

文献信息

• CONTROLLED RELEASE PREPARATION
  申请人：TAKEDA PHARMACEUTICAL COMPANY LIMITED

  公开号：US20160128945A1

  公开（公告）日：2016-05-12

  A controlled release preparation wherein the release of active ingredient is controlled, which releases an active ingredient for an extended period of time by staying or slowly migrating in the gastrointestinal tract, is provided by means such as capsulating a tablet, granule or fine granule wherein the release of active ingredient is controlled and a gel-forming polymer. Said tablet, granule or fine granule has a release-controlled coating-layer formed on a core particle containing an active ingredient.

  提供了一种受控释放制剂，其中活性成分的释放受到控制，通过在胃肠道内停留或缓慢迁移来延长时间释放活性成分，采用胶囊化片剂、颗粒或细颗粒的方式，其中活性成分的释放受到控制，并且使用了一种凝胶形成聚合物。所述的片剂、颗粒或细颗粒在含有活性成分的核心颗粒上形成了一个受控释放的涂层。
• NOVEL COMPOUNDS
  申请人：Gottschling Dirk

  公开号：US20110195954A1

  公开（公告）日：2011-08-11

  The present invention relates to new CGRP-antagonists of general formula I wherein U, V, X, Y, R 1 , R 2 , R 3 and R 4 are defined as mentioned in the description, the tautomers thereof, the isomers thereof, the diastereomers thereof, the enantiomers thereof, the hydrates thereof, the mixtures thereof and the salts thereof as well as the hydrates of the salts, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases, medicaments containing these compounds, the use thereof and processes for the preparation thereof.

  本发明涉及一般式I的新CGRP拮抗剂，其中U、V、X、Y、R1、R2、R3和R4如描述中所述定义，其互变异构体、异构体、顺反异构体、对映异构体、水合物、混合物及其盐，以及其盐的水合物，特别是与无机或有机酸或碱形成的生理上可接受的盐，包含这些化合物的药物、其用途以及其制备方法。
• 4-Substituted N-methyl-1,2,3,4-tetrahydroisoquinolines: synthesis via stereoselective substitution of tricarbonyl(N-methyl-1,2,3,4-tetrahydroisoquinoline)chromium
  作者：Julian Blagg、Stephen G. Davies、Bryan E. Mobbs

  DOI：10.1039/c39850000619

  日期：——

  Tricarbonyl(N-methyl-1,2,3,4-tetrahydroisoquinolines)chromium undergoes stereoselective 4-exo-deprotonation and subsequent electrophilic additions to generate the corresponding 4-exo-derivatives which after decomplexation yield 4-alkyl-, 4-phenyl-, and 4-hydroxy-N-methyl-1,2,3,4- tetrahydroisoquinolines.

  三羰基（N-甲基-1,2,3,4-四氢异喹啉）铬经历立体选择性4-外-去质子化反应，随后进行亲电加成生成相应的4-外-外衍生物，在分解后生成4-烷基-，4-苯基-和4-羟基-N-甲基-1,2,3,4-四氢异喹啉。
• [EN] PYRIDO[4,3-B]INDOLE AND PYRIDO[3,4-B]INDOLE DERIVATIVES AND METHODS OF USE<br/>[FR] DÉRIVÉS DE PYRIDO[4,3-B]INDOLE ET DE PYRIDO[3,4-B]INDOLE ET PROCÉDÉS D'UTILISATION
  申请人：MEDIVATION TECHNOLOGIES INC

  公开号：WO2011103430A1

  公开（公告）日：2011-08-25

  This disclosure is directed to tetracyclic pyrido[4,3-b]indole and pyrido[3,4-b]indoles. Pharmaceutical compositions comprising the compounds are also provided, as are methods of using the compounds in a variety of therapeutic applications, including the treatment of a cognitive disorder, psychotic disorder, neurotransmitter-mediated disorder and/or a neuronal disorder.

  本公开涉及四环吡啶并[4,3-b]吲哚和吡啶[3,4-b]吲哚。还提供了包含这些化合物的药物组合物，以及使用这些化合物进行各种治疗应用的方法，包括治疗认知障碍、精神病性障碍、神经递质介导的障碍和/或神经元障碍。
• ARYL- AND HETEROARYL-SUBSTITUTED TETRAHYDROISOQUINOLINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN
  申请人：MOLINO Bruce F.

  公开号：US20090253906A1

  公开（公告）日：2009-10-08

  The compounds of the present invention are represented by the chemical structure found in Formula (I): wherein: the carbon atom designated * is in the R or S configuration; and X is a fused bicyclic carbocycle or heterocycle selected from the group consisting of benzofuranyl, benzo[b]thiophenyl, benzoisothiazolyl, benzoisoxazolyl, indazolyl, indolyl, isoindolyl, indolizinyl, benzoimidazolyl, benzooxazolyl, benzothiazolyl, benzotriazolyl, imidazo[1,2-a]pyridinyl, pyrazolo[1,5-a]pyridinyl, [1,2,4]triazolo[4,3 -a]pyridinyl, thieno[2,3-b]pyridinyl, thieno[3,2-b]pyridinyl, 1H-pyrrolo[2,3-b]pyridinyl, indenyl, indanyl, dihydrobenzocycloheptenyl, tetrahydrobenzocycloheptenyl, dihydrobenzothiophenyl, dihydrobenzofuranyl, indolinyl, naphthyl, tetrahydronaphthyl, quinolinyl, isoquinolinyl, 4H-quinolizinyl, 9aH-quinolizinyl, quinazolinyl, cinnolinyl, phthalazinyl, quinoxalinyl, benzo[1,2,3]triazinyl, benzo[1,2,4]triazinyl, 2H-chromenyl, 4H-chromenyl, and a fused bicyclic carbocycle or fused bicyclic heterocycle optionally substituted with substituents (1 to 4 in number) as defined in R 14 ; with R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , and R 14 defined herein.

  本发明的化合物由公式（I）中的化学结构表示：其中：指定的碳原子*处于R或S构型；并且X是从苯并呋喃基，苯并[b]噻吩基，苯并异噻唑基，苯并异恶唑基，吲哚基，吲哚基，异吲哚基，吲哚吩基，苯并咪唑基，苯并噁唑基，苯并噻唑基，苯并三唑基，咪唑[1,2-a]吡啶基，吡唑并[1,5-a]吡啶基，[1,2,4]三唑并[4,3-a]吡啶基，噻吩并[2,3-b]吡啶基，噻吩并[3,2-b]吡啶基，1H-吡咯并[2,3-b]吡啶基，茚基，茚基，二氢苯并环庚烯基，四氢苯并环庚烯基，二氢苯并噻吩基，二氢苯并呋喃基，吲哚啉基，萘基，四氢萘基，喹啉基，异喹啉基，4H-喹唑啉基，9aH-喹唑啉基，喹嗪基，茚并吡啶基，邻苯二酚基，喹啉并苯并三唑基，2H-香豆素基，4H-香豆素基或者是一个融合的双环碳环或融合的双环杂环，可选地用定义在R14中的取代基（1到4个）取代；其中R1，R2，R3，R4，R5，R6，R7，R8和R14在此定义。